胆汁淤积性肝病的治疗

doi:10.3969/j.issn.1672-5069.2016.06.004

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (6): 650-653.doi: 10.3969/j.issn.1672-5069.2016.06.004

胆汁淤积性肝病的治疗

阎俪，马雄

200001上海市交通大学医学院附属仁济医院消化科/上海市消化疾病研究所

收稿日期:2016-09-18 出版日期:2016-11-10 发布日期:2016-11-28
通讯作者: 马雄，E-mail: maxiongmd@163.com

Treatment of cholestastic liver disease

Yan Li，Ma Xiong.

Division of Gastroenterology and Hepatology，Key Laboratory of Gastroenterology and Hepatology of Ministry of Health，State Key Laboratory for Oncogenes and Related Gene Study，Renji Hospital，JiaoTong University School of Medicine，Institute of Digestive Disease，Shanghai 200001，China

Received:2016-09-18 Online:2016-11-10 Published:2016-11-28
Contact: Ma Xiong，E-mail:maxiongmd@163.com

摘要/Abstract

关键词: 胆汁淤积性肝病, 胆汁性胆管炎, 硬化性胆管炎, 治疗

Key words: Cholestatic liver disease, Biliary cholangitis, Sclerosing cholangitis, Treatment

阎俪，马雄. 胆汁淤积性肝病的治疗[J]. 实用肝脏病杂志, 2016, 19(6): 650-653.

Yan Li，Ma Xiong.. Treatment of cholestastic liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 650-653.

[1] Dong M，Li J，Tang R，et al. Multiple genetic variants associated with primary biliary cirrhosis in a Han Chinese population. Clin Rev Allergy Immunol，2015，48（2-3）:316-321.
[2] Newton JL，Bhala N，Burt J，et al. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol，2006，44（4）:776-783.
[3] Quarneti C，Muratori P，Lalanne C，et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int，2015，35（2）:636-641.
[4] Beuers U，Kremer A E，Bolier R，et al. Pruritus in cholestasis: facts and fiction. Hepatology，2014，60（1）:399-407.
[5] Yang CY，Ma X，Tsuneyama K，et al. IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy. Hepatology，2014，59（5）:1944-1953.
[6] Shi J，Wu C，Lin Y，et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis:a meta-analysis of randomized controlled trials. Am J Gastroenterol，2006，101（7）:1529-1538.
[7] Zhang Y，Li S，He L，et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy:a meta-analysis. Drug Des Devel Ther，2015，9:2757-2766.
[8] Yin Q，Li J，Xia Y，et al. Systematic review and meta-analysis:bezafibrate in patients with primary biliary cirrhosis. Drug Design，Develop Ther，2015，9:5407.
[9] Rautiainen H，Karkkainen P，Karvonen AL，et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial. Hepatology，2005，41（4）:747-752.
[10] Hirschfield G M，Mason A，Luketic V，et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology，2015，148（4）:751-761. e8.
[11] Nevens F，Andreone P，Mazzella G，et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. New Engl J Med，2016，375（7）:631-643.
[12] Zhu G Q，Shi K Q，Huang G Q，et al. A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis. Oncotarget，2015，6（29）:26757.
[13] Eksteen B. Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis. Bri Med Bull，2014:ldu008.
[14] Mizuno S，Hirano K，Isayama H，et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci，2015，22（10）:766-770.
[15] Bjoro K，Brandseater B，Foss A，et al. Liver transplantation in primary sclerosing cholangitis//Seminars in liver disease. Copyright 2006 by Thieme Medical Publishers，Inc. 333 Seventh Avenue，New York，NY 10001，USA.，2006，26（1）:069-079.
[16] Graziadei IW，Wiesner RH，Marotta PJ，et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology，1999，30（5）:1121-1127.
[17] Brandsaeter B，Friman S，Broome U，et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scan J Gastroenterol，2003，38（11）:1176-1183.
[18] Eaton J E，Talwalkar J A，Lazaridis K N，et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology，2013，145（3）:521-536.
[19] Lammert F，Marschall HU，Glantz A，et al. Intrahepatic cholestasis of pregnancy:molecular pathogenesis，diagnosis and management. J Hepatol，2000，33（6）:1012-1021.
[20] Bacq Y，Sentilhes L，Reyes H B，et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy:a meta-analysis. Gastroenterology，2012，143（6）:1492-1501.
[21] Gurung V，Stokes M，Middleton P，et al. Interventions for treating cholestasis in pregnancy. Cochrane Library，2013.
[22] Folvik G，Hilde O，Helge GO. Benign recurrent intrahepatic cholestasis:review and long-term follow-up of five cases. Scan J Gastroenterol，2012，47（4）:482-488.
[23] Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol，2012，36:S26-S35.
[24] Morotti RA，Suchy FJ，Magid MS. Progressive familial intrahepatic cholestasis（PFIC） type 1，2，and 3:a review of the liver pathology findings//Seminars in liver disease. Thieme Medi Publishers，2011，31（1）:003-010.
[25] Sambrotta M，Strautnieks S，Papouli E，et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nature Genet，2014，46（4）:326-328.
[26] Gonzales E，Taylor SA，Davit-Spraul A，et al. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease. Hepatology，2016[ahead of print].
[27] Gomez-Ospina N，Potter CJ，Xiao R，et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nature Commun，2016[ahead of print].
[28] Davit-Spraul A，Fabre M，Branchereau S，et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis（PFIC）: Phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology，2010，51（5）:1645-1655.
[29] Frider B，Castillo A，Gordo-Gilart R，et al. Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3. Ann Hepatol，2015，14:745-751.
[30] Gonzales E，Grosse B，Schuller B，et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2:Evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology，2015，62（2）:558-566.
[31] Zhang H，Bernuzzi F，Lleo A，et al. Therapeutic potential of IL-17-mediated signaling pathway in autoimmune liver diseases. Mediat Inflammn，2015，2015.

胆汁淤积性肝病的治疗

Treatment of cholestastic liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[6]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[7]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[8]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[9]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[10]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[11]	李琪, 曾阿娟, 孟雯, 张海英, 李雪梅. 原发性胆汁性胆管炎患者胆囊病变临床分析[J]. 实用肝脏病杂志, 2019, 22(6): 924-927.
[12]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[13]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[14]	丁雯瑾, 范建高. 胆汁淤积性肝病相关并发症的处理^*[J]. 实用肝脏病杂志, 2019, 22(6): 938-940.
[15]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.